Mayson H. Alkhatib

450 total citations
43 papers, 325 citations indexed

About

Mayson H. Alkhatib is a scholar working on Oncology, Biomaterials and Molecular Biology. According to data from OpenAlex, Mayson H. Alkhatib has authored 43 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Biomaterials and 12 papers in Molecular Biology. Recurrent topics in Mayson H. Alkhatib's work include Nanoparticle-Based Drug Delivery (12 papers), Cancer, Lipids, and Metabolism (8 papers) and Chemotherapy-induced organ toxicity mitigation (6 papers). Mayson H. Alkhatib is often cited by papers focused on Nanoparticle-Based Drug Delivery (12 papers), Cancer, Lipids, and Metabolism (8 papers) and Chemotherapy-induced organ toxicity mitigation (6 papers). Mayson H. Alkhatib collaborates with scholars based in Saudi Arabia, Oman and Egypt. Mayson H. Alkhatib's co-authors include Huda Mohammed Alkreathy, Magda M. Aly, Douglas G. Hayes, Volker S. Urban, Nadia Osman, Aftab Ahmad, Madeha N. Al‐Seeni, Ahmed Esmat, Saudi Arabia and Maryam A. Al-Ghamdi and has published in prestigious journals such as Scientific Reports, Colloids and Surfaces A Physicochemical and Engineering Aspects and Biomedicine & Pharmacotherapy.

In The Last Decade

Mayson H. Alkhatib

40 papers receiving 310 citations

Peers

Countries citing papers authored by Mayson H. Alkhatib

Since Specialization

Citations

This map shows the geographic impact of Mayson H. Alkhatib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mayson H. Alkhatib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mayson H. Alkhatib more than expected).

Fields of papers citing papers by Mayson H. Alkhatib

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mayson H. Alkhatib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mayson H. Alkhatib. The network helps show where Mayson H. Alkhatib may publish in the future.

Co-authorship network of co-authors of Mayson H. Alkhatib

This figure shows the co-authorship network connecting the top 25 collaborators of Mayson H. Alkhatib. A scholar is included among the top collaborators of Mayson H. Alkhatib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mayson H. Alkhatib. Mayson H. Alkhatib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ANTIMICROBIAL ACTIVITY OF CHITOSAN-VITAMIN E-NANOEMULSION 2023 ·Journal of Microbiology Biotechnology and Food Sciences ·Mayson H. Alkhatib, (unknown), (unknown), Abdullah M. S. Al‐Hatmi, (unknown), (unknown)	2
2	Growth and invasion inhibition of T47D ductal carcinoma cells by the association of docetaxel with a bioactive agent in neutral nanosuspension 2023 ·Bioimpacts ·(unknown), Mayson H. Alkhatib	4
3	Antitumor Activities of Co-loading Gemcitabine and Oxaliplatin into Oleic Acid-Based Solid Lipid Nanoparticle against Non-Small Cell Lung Cancer Cells 2021 ·Biointerface Research in Applied Chemistry ·(unknown), Mayson H. Alkhatib, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	14
4	Doxorubicin supplemented with pravastatin in lipid nanoemulsion induces antineoplastic activity with limited hepatotoxicity and cardiotoxicity in tumor-bearing mice 2021 ·Asian Journal of Pharmaceutical Research and Health Care ·Mayson H. Alkhatib, Huda Mohammed Alkreathy, (unknown), (unknown), (unknown), Ahmed Esmat	5
5	Carvacrol effect on topotecan cytotoxicity in various human cancer cells in vitro 2021 ·Pharmacia ·(unknown), Mayson H. Alkhatib, Madeha N. Al‐Seeni	10
6	Incorporation of docetaxel and thymoquinone in borage nanoemulsion potentiates their antineoplastic activity in breast cancer cells 2020 ·Scientific Reports ·Mayson H. Alkhatib, (unknown), (unknown)	31
7	Carrying epirubicin on nanoemulsion containing algae and cinnamon oils augments its apoptotic and anti-invasion effects on human colon cancer cells. 2020 ·PubMed ·Mayson H. Alkhatib, (unknown), (unknown)	6
8	Incorporation of ifosfamide into various essential oils -based nanoemulsions ameliorates its apoptotic effect in the cancers cells 2019 ·Scientific Reports ·Mayson H. Alkhatib, (unknown), Huda Mohammed Alkreathy	19
9	Antineoplastic activity of mitomycin C formulated in nanoemulsions-based essential oils on HeLa cervical cancer cells 2018 ·Chemico-Biological Interactions ·Mayson H. Alkhatib, (unknown), (unknown)	18
10	In vivo evaluation of the anticancer activity of the gemcitabine and doxorubicin combined in a nanoemulsion 2018 ·Journal of Pharmacy And Bioallied Sciences ·Mayson H. Alkhatib, (unknown), (unknown)	5
11	Cytotoxicity and apoptosis enhancement in breast and cervical cancer cells upon coadministration of mitomycin C and essential oils in nanoemulsion formulations 2018 ·Biomedicine & Pharmacotherapy ·(unknown), Mayson H. Alkhatib, (unknown)	52
12	PRODUCTION OF THE ANTITUMOR L-GLUTAMINASE ENZYME FROM THERMOTOLERANT Streptomyces sp. D214, UNDER SUBMERGED FERMENTATION CONDITIONS 2017 ·Journal of Experimental Biology and Agricultural Sciences ·Magda M. Aly, (unknown), (unknown), (unknown), Mayson H. Alkhatib, (unknown), (unknown)	13
13	Anticancer Activity of Mixed Doxorubicin and Pravastatin in Nanoemulsions Against HCT 116 Colon Cancer Cells 2017 ·International Journal of Drug Delivery Technology ·Mayson H. Alkhatib, (unknown), (unknown)	1
14	Antitumor activity of mixing gemcitabine with pravastatin in a microemulsion against a549 non-small cell lung cancer cells 2017 ·International Journal of Pharma and Bio Sciences ·Mayson H. Alkhatib, (unknown), (unknown)	2
15	Cytotoxic Effect of the Combination of Gemcitabine and Atorvastatin Loaded in Nanoparticle on the MCF-7 Breast Cancer Cells and HFS Human Foreskin Cells 2017 ·Current Nanoscience ·Mayson H. Alkhatib, (unknown)	6
16	Antimicrobial Activity of Biocompatible Microemulsions Against Aspergillus niger and Herpes Simplex Virus Type 2 2016 ·Jundishapur Journal of Microbiology ·Mayson H. Alkhatib, Magda M. Aly, (unknown), (unknown)	5
17	Antitumor activity of doxorubicine-loaded nanoemulsion against Ehrlich ascites carcinoma-bearing mice 2016 ·Tropical Journal of Pharmaceutical Research ·Mayson H. Alkhatib, Huda Mohammed Alkreathy, (unknown), (unknown)	6
18	CYTOTOXICITY EFFECT OF DOCETAXEL-LOADED-MICROEMULSION IN A549 NON-SMALL CELL LUNG CANCER AND HCT116 COLON CANCER CELLS 2014 ·International Journal of Pharma and Bio Sciences ·Mayson H. Alkhatib, (unknown), Saudi Arabia	3
19	ANTICANCER EFFECT OF DOCETAXEL ENCAPSULATED IN A CAPRYOL 90/ CREMOPHOR EL/TRANSCUTOL MICROEMULSION AGAINST MCF-7 BREAST CANCER CELLS 2014 ·Journal of Experimental Biology and Agricultural Sciences ·Mayson H. Alkhatib, (unknown)	1
20	Impact of Nanoparticles on Cancer Therapy 2013 ·Tropical Journal of Pharmaceutical Research ·Mayson H. Alkhatib, (unknown), (unknown)	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact